| scholarly article | Q13442814 |
| P2093 | author name string | Angehrn P | |
| Stieger M | |||
| Gmünder H | |||
| Wohlgensinger B | |||
| P2860 | cites work | 4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction | Q40085967 |
| Cyclothialidine and its congeners: a new class of DNA gyrase inhibitors | Q40667220 | ||
| Cloning and characterization of a DNA gyrase B gene from Streptomyces sphaeroides that confers resistance to novobiocin | Q41875356 | ||
| Deoxyribonucleic acidgyrase-deoxyribonucleic acid complex containing 140 base pairs of deoxyribonucleic acid and an .alpha.2.beta.2 protein core | Q44056419 | ||
| Preliminary crystallographic analysis of the ATP-hydrolysing domain of the Escherichia coli DNA gyrase B protein | Q45203137 | ||
| Cyclothialidine, a novel DNA gyrase inhibitor. I. Screening, taxonomy, fermentation and biological activity. | Q48798251 | ||
| The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. | Q52399144 | ||
| gyrB mutations which confer coumarin resistance also affect DNA supercoiling and ATP hydrolysis by Escherichia coli DNA gyrase. | Q54269895 | ||
| Probing the limits of the DNA breakage-reunion domain of the Escherichia coli DNA gyrase A protein. | Q54700296 | ||
| Crystallization of Inhibitor Complexes of an N-Terminal 24 kDa Fragment of the DNA Gyrase B Protein | Q59695056 | ||
| The 24 kDa N-terminal sub-domain of the DNA gyrase B protein binds coumarin drugs | Q59695062 | ||
| DNA topoisomerases | Q70095180 | ||
| Mapping the active site tyrosine of Escherichia coli DNA gyrase | Q70170795 | ||
| Cyclothialidine, a novel DNA gyrase inhibitor. II. Isolation, characterization and structure elucidation | Q72272344 | ||
| Characterization of the binding site for cyclothialidine on the B subunit of DNA gyrase | Q72315721 | ||
| Cloning and characterization of a DNA gyrase A gene from Escherichia coli that confers clinical resistance to 4-quinolones. | Q33742392 | ||
| DNA gyrase: an enzyme that introduces superhelical turns into DNA | Q34013173 | ||
| Crystal structure of an N-terminal fragment of the DNA gyrase B protein. | Q34493198 | ||
| DNA gyrase: structure and function. | Q34507230 | ||
| Fluoroquinolone antimicrobial agents | Q34613302 | ||
| Novobiocin and coumermycin inhibit DNA supercoiling catalyzed by DNA gyrase | Q35042255 | ||
| Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations | Q35810189 | ||
| Energy coupling in DNA gyrase and the mechanism of action of novobiocin | Q35994466 | ||
| Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae | Q36753284 | ||
| DNA gyrase: subunit structure and ATPase activity of the purified enzyme | Q37596172 | ||
| An unusual mechanism for resistance to the antibiotic coumermycin A1 | Q37603477 | ||
| Structure-activity relationships in DNA gyrase inhibitors | Q37902823 | ||
| Inhibitors of DNA gyrase | Q38333670 | ||
| Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli | Q39816339 | ||
| Ser-127-to-Leu substitution in the DNA gyrase B subunit of Streptococcus pneumoniae is implicated in novobiocin resistance | Q39837651 | ||
| A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex | Q39864841 | ||
| Biological characterization of cyclothialidine, a new DNA gyrase inhibitor | Q39883723 | ||
| Cloning, sequencing, and expression of the DNA gyrase genes from Staphylococcus aureus | Q39928815 | ||
| Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins | Q39936506 | ||
| Mutations in DNA gyrase result in novobiocin resistance in halophilic archaebacteria | Q39938412 | ||
| DNA gyrase gyrA mutations in ciprofloxacin-resistant strains of Staphylococcus aureus: close similarity with quinolone resistance mutations in Escherichia coli | Q39952187 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| P304 | page(s) | 1060-1062 | |
| P577 | publication date | 1996-04-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | GyrB mutations in Staphylococcus aureus strains resistant to cyclothialidine, coumermycin, and novobiocin | |
| P478 | volume | 40 |
| Q34446438 | Accumulation of mutations in both gyrB and parE genes is associated with high-level resistance to novobiocin in Staphylococcus aureus |
| Q39731838 | Active-site residues of Escherichia coli DNA gyrase required in coupling ATP hydrolysis to DNA supercoiling and amino acid substitutions leading to novobiocin resistance |
| Q54111068 | Adaptive acquisition of novobiocin resistance in Pasteurella multocida strains of avian origin. |
| Q33921234 | Antimicrobial resistance in Staphylococcus aureus |
| Q51824682 | Attempt to develop live attenuated bacterial vaccines by selecting resistance to gossypol, proflavine hemisulfate, novobiocin, or ciprofloxacin. |
| Q37335706 | Biological evaluation of benzothiazole ethyl urea inhibitors of bacterial type II topoisomerases |
| Q30988207 | Brachyspira (Serpulina) hyodysenteriae gyrB mutants and interstrain transfer of coumermycin A(1) resistance |
| Q40902870 | DNA gyrase as a drug target |
| Q41822811 | Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds |
| Q34214929 | Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. |
| Q45005861 | Fitness cost, gyrB mutation, and absence of phosphotransferase system fructose specific IIABC component in novobiocin-resistant Streptococcus iniae vaccine strain ISNO. |
| Q93083428 | Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes |
| Q47722715 | Identification of gyrB and rpoB gene mutations and differentially expressed proteins between a novobiocin-resistant Aeromonas hydrophila catfish vaccine strain and its virulent parent strain |
| Q41668866 | In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-Negative, and atypical bacteria |
| Q34510396 | In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class |
| Q42631623 | Molecular characterization of the gyrB region of the oral spirochete, Treponema denticola |
| Q33701326 | Mutations in Bartonella bacilliformis gyrB confer resistance to coumermycin A1. |
| Q33690598 | Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity |
| Q39731985 | Resistance genes of aminocoumarin producers: two type II topoisomerase genes confer resistance against coumermycin A1 and clorobiocin |
| Q28534970 | Synthesis, structure and antibacterial activity of potent DNA gyrase inhibitors: N'-benzoyl-3-(4-bromophenyl)-1H-pyrazole-5-carbohydrazide derivatives |
| Q47932274 | The genome of Staphylococcus aureus: a review |
Search more.